Only two from the %CV values were higher than our desired acceptable value of 20%

Only two from the %CV values were higher than our desired acceptable value of 20%. GM-CSF) were undetectable and five analytes (RANTES, MCP-1, VEGF, MIP-1 and PDGF-BB) showed significant difference in concentrations at Day 0 compared to Day 7. == Conclusions == The current study demonstrated higher variations Neuronostatin-13 human in cytokine levels among individuals than were observed for samples obtained one week apart from identical donors. These data suggest that a serum sample from each subject for use as a baseline measurement is a better control for clinical trials rather than sera from a paired cohort. == Introduction == Cytokines and chemokines are soluble molecules important for regulation of cell function in the innate and adaptive immune responses. Cytokines play a significant role in intercellular signaling in inflammatory reactions and hematopoiesis [1] whereas chemokines play a major role in chemotaxis in events such as inflammation or angiogenesis. Measurement of these immune mediators has become Neuronostatin-13 human increasingly important as a means of understanding immune responses during the course of disease or infections, or in response to therapy and interventions. As these are soluble molecules, the detection and measurement of cytokines and chemokines generally relies on antibody-based capture techniques such as ELISA. Since the total number of known cytokines and chemokines is well over one hundred, single-plex assays for these are of limited utility when attempting to measure these as part of a broad profiling of immune responses in clinical protocols or trials. In the past few years, increased interest in biomarker research has pushed forward the development of multiplexing tools. Biomarker studies allow researchers to examine and characterize a disease state in a noninvasive manner, and to correlate changes in the biomarker to disease status or therapy. While some biomarkers are critical for the early diagnosis of many chronic diseases, including heart diseases, diabetes, and cancer [1,2], others provide prognostic information or a better understanding of the pathogenesis of diseases. Many clinical studies involve the correlation between the presence and biological activity of cytokines and chemokines, as they are crucial for the understanding of many immunological functions [3]. Bead based multiplex immunoassay technologies to measure biomarkers have the capability of measuring up to 100 cytokines/chemokines simultaneously in a minimal amount of biological sample [4] and are becoming increasingly available. When conditions are carefully controlled, these multiplex assays can achieve similar results to those obtained Neuronostatin-13 human by ELISA techniques [5]. Determining the accuracy and reliability of the detection of each analyte is key for the development of multiplex clinical tests and in using these in clinical trials. Our lab has examined potential sources of variation in these assays. For example, we found that quantification of cytokines varies greatly depending on which commercial kit is used for these determinations [6]. In recent studies, we compared the measurement of analytes in serum to those in plasma and found that these differ significantly for many analytes [7]. We have also looked at the impact of various anticoagulants on cytokine measurements in plasma [8] and again show that these can significantly impact the measurements of various analytes. Together these studies illustrate the need for strict uniformity in sample MYH9 collection and preparation, as well as assay performance in order to obtain reproducible results. By understanding the limitations on sample collection and assay performance, questions could then be Neuronostatin-13 human asked regarding the biologic variations that might.